[Fibrates therapy: Rational use fenofibrate 2016. Executive summary]

Abstract

To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.

Keywords: Atherogenic dyslipidemia; Cardiovascular risk; Dislipidemia aterogénica; Fenofibrate; Fenofibrato; Fibrates; Fibratos; Riesgo cardiovascular; Triglicéridos; Triglycerides.